Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender WomenLinda‐Gail Bekker, Flavia Matovu Kiweewa, Moupali Das et al.|New England Journal of Medicine|2024Cited by 471
What's Love Got to Do With It? Explaining Adherence to Oral Antiretroviral Pre-Exposure Prophylaxis for HIV-Serodiscordant CouplesNorma C. Ware, David R. Bangsberg, Monique A. Wyatt et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2012Cited by 254
Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trialOnyema Ogbuagu, Jason Flamm, Peter Ruane et al.|The Lancet HIV|2021Cited by 91
A comparison of all-cause and cause-specific mortality by household socioeconomic status across seven INDEPTH network health and demographic surveillance systems in sub-Saharan AfricaMatthew M Coates, Gene Bukhman, Marylene Wamukoya et al.|Global Health Action|2019Cited by 27